Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Platelet-derived Growth Factor | Platelet-derived Growth Factor (PDGF) is a growth factor that regulates the growth of cells and blood vessels. PDGF consists of five isoforms, including PDGF-AA (PDGFA), -BB (PDGFB), -CC (PDGFC), and -DD (PDGFD), and -AB (a PDGFA and PDGFB heterodimer). Synonyms: PDGF. |  |
| 1-[2-[5- (2-Methoxyethoxy) benzimidazol-1-yl]quinolin-8-yl]piperidin-4-ylamine | 1-[2-[5- (2-Methoxyethoxy) benzimidazol-1-yl]quinolin-8-yl]piperidin-4-ylamine exhibits antiangiogenic and antitumor properties. It is an inhibitor of platelet-derived growth factor receptor β (PDGFR- β). Group: Biochemicals. Grades: Highly Purified. CAS No. 343787-29-1. Pack Sizes: 1mg, 2.5mg. Molecular Formula: C24H27N5O2, Molecular Weight: 417.5. US Biological Life Sciences. |  Worldwide |
| 1-Stearo-2-linolein | 1-Stearo-2-linolein is used in the study of the influence of platelet-derived growth factor (PDGF) on diacylglycerol phosphorylation in Swiss 3T3 cells. It is also a possible protein kinase C activator. Group: Biochemicals. Grades: Highly Purified. CAS No. 27095-10-9. Pack Sizes: 10mg, 100mg. Molecular Formula: C39H72O5, Molecular Weight: 620.99. US Biological Life Sciences. | Worldwide |
| 1-Stearo-2-linolein-d5 | 1-Stearo-2-linolein-d5 is labelled 1-Stearo-2-linolein (S686465) which is used in the study of the influence of platelet-derived growth factor (PDGF) on diacylglycerol phosphorylation in Swiss 3T3 cells. It is also a possible protein kinase C activator. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 1mg, 10mg. Molecular Formula: C39H67D5O5, Molecular Weight: 626.02. US Biological Life Sciences. | Worldwide |
| 1-Stearoyl-2-linoleoyl-sn-glycerol | 1-Stearoyl-2-linoleoyl-sn-glycerol is used in the study of the influence of platelet-derived growth factor (PDGF) on diacylglycerol phosphorylation in Swiss 3T3 cells. It is also a possible protein kinase C activator. Group: Biochemicals. Grades: Highly Purified. CAS No. 34487-26-8. Pack Sizes: 10mg, 25mg. Molecular Formula: C39H72O5, Molecular Weight: 620.99. US Biological Life Sciences. | Worldwide |
| AC710 | AC710 is a potent, selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity. AC710 is now a preclinical development candidate. Synonyms: AC 710; AC-710. Grades: >98%. CAS No. 1351522-04-7. Molecular formula: C31H42N6O4. Mole weight: 562.7. | |
| AG 126 | Tyrphostins are protein tyrosine kinase inhibitors developed to inhibit cell growth through blocking the activity of certain GFRK (growth factor receptor kinases). AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM. It also inhibits the production of TNF-α (tumor necrosis factor-α), attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in animal models. AG 126 is a poor inhibitor of epidermal GFRK with IC50 of 450 μM and platelet-derived GFRK with IC50 > 100 μM. AG 126 may represent a new approach for the therapy of inflammation. Uses: Anti- inflammation. Synonyms: AG126; AG-126; Tyrphostin AG 126; UNII-7YA4AMD1JC; Tyrphostin A 10; alpha-Cyano-(3-hydroxy-4-nitro)cinnamonitrile. Grades: 95%. CAS No. 118409-62-4. Molecular formula: C10H5N3O3. Mole weight: 215.16. | |
| AG1295 | Tyrphostin AG 1295 is a selective inhibitor of PDGFR (platelet-derived growth factor receptor) protein tyrosine kinase (PDGF-receptor PTK)(IC50 = 500 nM) and PDGF-dependent DNA synthesis (IC50 = 2.5 μM) in Swiss/3T3 cells. Synonyms: AG1295; AG 1295; AG 1295; NSC 380341; NSC380341; NSC-380341; Tyrphostin AG 1295. Grades: >98%. CAS No. 71897-07-9. Molecular formula: C16H14N2. Mole weight: 234.30. | |
| Ansornitinib | Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ANG-3070. CAS No. 1448874-96-1. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147243. |  |
| Barnidipine hydrochloride | Barnidipine (Mepirodipine) hydrochloride is an L-type calcium antagonist ( CaA ) with high affinity for [ 3 H] initrendipine binding sites ( K i = 0.21 nmol/L, has selective action against CaA receptors. Barnidipine hydrochloride is an orally active antihypertensive agent that can reduce the level of platelet-derived growth factor B-chain mRNA and peripheral vascular resistance [1] [2] [3] [4]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Mepirodipine hydrochloride; YM-09730-5. CAS No. 104757-53-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-107322. | |
| BLZ945 | BLZ945 is an orally active, potent and selective CSF-1R inhibitor, which inhibits CSF-1R activity with an IC50 of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor beta (PDGFRb). Synonyms: sotuletinib; BLZ 945; BLZ-945. Grades: >98%. CAS No. 953769-46-5. Molecular formula: C20H22N4O3S. Mole weight: 398.48. | |
| CP-547632 | CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor , and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM. After oral administration of CP-547,632 to mice bearing NIH3T3/H-ras tumors, VEGFR-2 phosphorylation in tumors was inhibited in a dose-dependent fashion (EC50 590 ng/ml). CP-547,632 is a well-tolerated, orally-bioavailable inhibitor presently under clinical investigation for the treatment of human malignancies. Synonyms: CP547632; CP 547632; CP-547632; PAN90806; PAN 90806; PAN-90806; CP632; OSI632; CP 632; OSI 632; CP-632; OSI-632. CAS No. 252003-65-9. Molecular formula: C20H24BrF2N5O3S. Mole weight: 532.405. | |
| Crenolanib | Crenolanib is an orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. PDGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. Synonyms: CP 868596; CP868596; CP-868596; ARO 002; RO-002; RO002; Crenolanib. CAS No. 670220-88-9. Molecular formula: C26H29N5O2. Mole weight: 443.551. | |
| DMPQ dihydrochloride | DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC 50 of 80 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1123491-15-5. Pack Sizes: 1 mg. Product ID: HY-108627. | |
| Esculetin | Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities [1]. Uses: Scientific research. Group: Natural products. CAS No. 305-01-1. Pack Sizes: 10 mM * 1 mL; 100 mg. Product ID: HY-N0284. | |
| Henatinib | Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta. Synonyms: (R,Z)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-(2-hydroxy-3-morpholin-4-yl-propyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c]azepin-4-one. CAS No. 1239269-51-2. Molecular formula: C25H29FN4O4. Mole weight: 468.53. | |
| Imatinib free base | Imatinib is a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Imatinib was approved for medical use in the United States in 2001. Group: Inhibitors. Alternative Names: CGP 57148; CGP57148; CGP-57148; CGP57148B; CGP-57148B; CGP 57148B; STI571; STI-571; STI 571. CAS No. 152459-95-5. Molecular formula: C29H31N7O. Mole weight: 493.62. Appearance: White to off-white to brownish or yellowish tinged crystalline powder. Purity: >98%. IUPACName: N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide. Canonical SMILES: O=C (NC1=CC=C (C)C (NC2=NC=CC (C3=CC=CN=C3)=N2)=C1)C4=CC=C (CN5CCN (C)CC5)C=C4. Catalog: ACM152459955. |  |
| JI-101 | JI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Angiogenesis inhibitor JI-101 binds to and inhibits VEGFR2, PDGFRb and EphB4, which may inhibit tumor angiogenesis and, so, cellular proliferation in tumor cells overexpressing VEGFR2, PDGFRb and EphB4. The receptor tyrosine kinases VEGFR2, PDGFRb and EphB4 may be overexpressed in a number of different cancer cell types and may play crucial roles in tumor angiogenesis. Synonyms: N-[1-[(2-Amino-4-pyridinyl)methyl]-1H-indol-4-yl]-N'-(5-bromo-2-methoxyphenyl)urea; 1-[1-[(2-Aminopyridin-4-yl)methyl]-1H-indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea; CGI 1842; JI101; JI 101. Grades: 98%. CAS No. 900573-88-8. Molecular formula: C22H20BrN5O2. Mole weight: 466.33. | |
| JNJ-10198409 | JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor ( IC 50 =2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase ( IC 50 =4.2 nM) and PDGFR-α kinase ( IC 50 =45 nM) [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 627518-40-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg. Product ID: HY-W011266. | |
| Linifanib | Description of Linifanib: Linifanib is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3). Synonyms: ABT869; ABT 869; ABT-869; Linifanib. CAS No. 796967-16-3. Molecular formula: C21H18FN5O. Mole weight: 375.407. | |
| mitogen-activated protein kinase kinase | This enzyme is a dual-specific protein kinase and requires mitogen-activated protein kinase kinase kinase (MAPKKK) for activation. It is required for activation of EC 2.7.11.24, mitogen-activated protein kinase. Phosphorylation of MEK1 by Raf involves phosphorylation of two serine residues. Mitogen-activated protein kinase (MAPK) signal transduction pathways are among the most widespread mechanisms of cellular regulation. Mammalian MAPK pathways can be recruited by a wide variety of stimuli including hormones (e.g. insulin and growth hormone), mitogens (e.g. epidermal growth factor and platelet-derived growth factor), vasoactive peptides (e.g. angiotensin-II and endothelin), inflammatory cytokines of the tumour necrosis factor (TNF) family and environmental stresses such as osmotic shock, ionizing radiation and ischaemic injury. Group: Enzymes. Synonyms: MAP kinase kinase; MAP kinase kinase 4; MAP kinase kinase 7; MAP kinase or ERK . Enzyme Commission Number: EC 2.7.12.2. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3162; mitogen-activated protein kinase kinase; EC 2.7.12.2; MAP kinase kinase; MAP kinase kinase 4; MAP kinase kinase 7; MAP kinase or ERK kinase; MAP2K; MAPKK; MAPKK1; MEK; MEK1; MEK2; MKK; MKK2; MKK4; MKK6; MKK7; STK27. Cat No: EXWM-3162. |  |
| Motesanib | Motesanib is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors. It also potently inhibits angiogenesis and induces regression in tumor xenografts. Uses: Protein kinase inhibitors. Synonyms: N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide; AMG 706; AMG706; AMG706; motesanib. Grades: >98%. CAS No. 453562-69-1. Molecular formula: C22H23N5O. Mole weight: 373.45. | |
| Nilotinib monohydrochloride monohydrate | Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. It also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). Uses: Tyrosine kinase inhibitors. Synonyms: AMN-107; AMN 107; AMN107; Tasigna. Grades: >98%. CAS No. 923288-90-8. Molecular formula: C28H25ClF3N7O2. Mole weight: 583.99. | |
| ON-123300 | ON123300 is a potent multikinase inhibitor and may be potential useful for brain tumor chemotherapy. ON123300 strongly inhibits Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as β-type platelet-derived growth factor receptor (PDGFRβ). ON123300 inhibits U87 glioma cell proliferation with an IC(50) 3.4 ± 0.1 μmol/L. ON123300 exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. ON123300 might be an effective agent in MCL, including ibrutinib-resistant forms of the disease. Group: Inhibitors. Alternative Names: ON-123300; ON 123300; ON123300; Narazaciclib. CAS No. 1357470-29-1. Molecular formula: C24H27N7O. Mole weight: 429. Appearance: Solid powder. Purity: >98%. IUPACName: 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. Canonical SMILES: N#CC1=CC2=CN=C (NC3=CC=C (N4CCN (C)CC4)C=C3)N=C2N (C5CCCC5)C1=O. Catalog: ACM1357470291. | |
| PD089828 | PD089828 is a potent FGFR inhibitor, which inhibits human full-length fibroblast growth factor (FGF) receptor-1 (FGFR-1), platelet-derived growth factor (PDGF) receptor beta subunit (PDGFR-beta), Src nonreceptor tyrosine kinase (c-Src) and epidermal growth factor (EGF) receptor (EGFR) tyrosine kinases with half-maximal inhibitory potencies (IC50 values) of 0.15 +/- 0.02 (n = 4), 0.18 +/- 0.04 (n = 3), 1.76 +/- 0.28 (n = 4) and 5.47 +/- 0.78 (n = 6) microM, respectively. The results highlight the biological characteristics of PD 089828 as a novel, broadly active protein tyrosine kinase inhibitor with long-lasting but reversible cellular effects. The potential therapeutic use of these broadly acting, nonselective inhibitors as antiproliferative and antimigratory agents could extend to such diseases as cancer, atherosclerosis and restenosis in which redundancies in growth-signaling pathways are known to exist. Synonyms: PD-089828; PD 089828; N-[2-Amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; 1-[2-Amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-(2-methyl-2-propanyl)urea; EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor. Grades: ≥98%. CAS No. 179343-17-0. Molecular formula: C18H18Cl2N6O. Mole weight: 405.28. | |
| PD 166285 dihydrochloride | PD 166285, a novel protein tyrosine kinase inhibitor of a new structural class, is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1), and PDGFRβ (platelet-derived growth factor receptor β) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). PD 166285 also inhibits the checkpoint kinases Wee1 and MYT1 (Myt1), abolishes Cdc2 phosphorylation in numerous tumor cell lines, and abrogates the G2 checkpoint. Synonyms: PD 166285 dihydrochloride; PD166285 dihydrochloride; PD-166285 dihydrochloride6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one dihydrochloride. Grades: ≥99% by HPLC. CAS No. 212391-63-4. Molecular formula: C26H27Cl2N5O2.2HCl. Mole weight: 585.35. | |
| Petunidin chloride | Petunidin chloride is an O-methylated anthocyanidin derived from delphinidin. Petunidin chloride binds with and suppresses the activity of focal adhesion kinase and to inhibit platelet-derived growth factor-induced aortic smooth muscle cell migration, which may confer a protective effect against atherosclerosis. Uses: Scientific research. Group: Natural products. CAS No. 1429-30-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-126410. | |
| picropodophyllin | Picropodophyllin, also known as Picropodophyllotoxin, AXL1717 or PPP, is a cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Picropodophyllin specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT). This agent shows potent activity in the suppression o f tumor cell proliferation and the induction of tumor cell apoptosis. IGF1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a critical role in the growth and survival of many types of cancer cells. Synonyms: AXL1717; AX-L1717; AXL 1717; PPP; Picropodophyllotoxin. Grades: >98%. CAS No. 477-47-4. Molecular formula: C22H22O8. Mole weight: 414.41. | |
| R1530 | R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta, FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis. Synonyms: R-1530; R 1530. Grades: >98%. CAS No. 882531-87-5. Molecular formula: C18H14ClFN4O. Mole weight: 356.78136. | |
| Radotinib | Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. Check for active clinical trials or closed clinical trials using this agent. Synonyms: IY-5511; IY 5511; IY5511; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide. Grades: >98%. CAS No. 926037-48-1. Molecular formula: C27H21F3N8O. Mole weight: 530.515. | |
| SAR-407899 | SAR-407899 is a potent, ATP-competitive ROCK inhibitor. It is equipotent against human and rat-derived Rho-kinase 2 with inhibition constant values of 36 nM and 41 nM, respectively. It is highly selective in panel of 117 receptor and enzyme targets in vitro. It demonstrated concentration-dependent inhibition of Rho-kinase-mediated phosphorylation of myosin phosphatase, platelet-derived growth factor-induced proliferation, thrombin-induced stress fiber formation, and monocyte chemotactic protein-1-stimulated chemotaxis in vitro. It potently inhibits endothelin-1-induced constriction of renal resistance arteries. It has good antihypertensive activity and lowered blood pressure in a variety of rodent models. Uses: Sar-407899 has good antihypertensive activity. Synonyms: SAR407899; SAR 407899; SAR-407899; 6-Piperidin-4-yloxy-2H-isoquinolin-1-one;6-(Piperidin-4-yloxy)isoquinolin-1(2H)-one. Grades: >98 %. CAS No. 923359-38-0. Molecular formula: C14H16N2O2. Mole weight: 244.29. | |
| Sennoside B | Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis [1] [2]. Uses: Scientific research. Group: Natural products. CAS No. 128-57-4. Pack Sizes: 10 mg; 25 mg; 50 mg. Product ID: HY-N0366. | |
| SKLB610 | SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, respectively, at concentration of 10μM in biochemical kinase assays. SKLB610 exhibited its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity. Its potential to be a candidate of anticancer agent is worth being further investigated. Synonyms: SKLB610; SKLB 610; SKLB-610. Grades: 0.98. CAS No. 1125780-41-7. Molecular formula: C21H16F3N3O3. Mole weight: 415.372. | |
| SU14813 | SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3) (1). SU14813 was developed as a next-generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice. Synonyms: SU 14813; SU-14813; SU014813; SU-014813; SU 014813. Grades: >98%. CAS No. 627908-92-3. Molecular formula: C23H27FN4O4. Mole weight: 442.491. | |
| SU14813 maleate | SU14813 maleate is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3). It was developed as a next-generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. It demonstrated broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice. Synonyms: SU14813 maleate; SU 14813 maleate; SU-14813 maleate. Grades: >98%. CAS No. 849643-15-8. Molecular formula: C27H31FN4O8. Mole weight: 558.56. | |
| SU 16f | SU 16f is a potent and selective platelet-derived growth factor receptor β (PDGFRβ) inhibitor (IC50 = 10 nM), displaying > 14-fold, > 229-fold and > 10000-fold selectivity over VEGFR2, FGFR1 and EGFR respectively. It also inhibits VEGF receptor 2. SU 16f has been shown to inhibit proliferation of HUVEC and NIH3T3 cells in vitro (IC50 = 0.11 μM). Synonyms: 3-[2,4-dimethyl-5-[(Z)-(2-oxo-6-phenyl-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; 5-[1,2-Dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid; SU-16F. Grades: >98%. CAS No. 251356-45-3. Molecular formula: C24H22N2O3. Mole weight: 386.44. | |
| SU4984 | SU4984 is a protein tyrosine kinase inhibitor used in cancer research with an IC50 of 10-20 μM against fibroblast growth factor receptor 1 (FGFR1). It also inhibits platelet-derived growth factor receptor and insulin receptor. Synonyms: SU-4984; SU 4984; 1-Piperazinecarboxaldehyde, 4-[4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]phenyl]-; 4-{4-[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]phenyl}-1-piperazinecarbaldehyde; 4-(4-((2-Oxoindolin-3-ylidene)methyl)phenyl)piperazine-1-carbaldehyde. Grades: ≥95%. CAS No. 186610-89-9. Molecular formula: C20H19N3O2. Mole weight: 333.38. | |
| SU5408 | A potent, selective and cell-permeable inhibitor of VEGFR2 kinase(IC50= 70 nM) with little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50 > 100 μM). Synonyms: SU-5408; SU 5408; SU5408; ethyl 2,4-dimethyl-5-[(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrole-3-carboxylate; VEGFR2 Kinase Inhibitor I; IN1018. CAS No. 15966-93-5. Molecular formula: C18H18N2O3. Mole weight: 310.35. | |
| Sunitinib Maleate (Sutent, Sunitinib Malate, SU-11248, PHA-290940AD, PNU-290940AD) | A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple receptor tyrosine kinases, including platelet-derived growth factor receptor and vascular endothelial growth factor receptor, that are associated with tumor growth and angiogenesis. Group: Biochemicals. Alternative Names: Sutent. Grades: Highly Purified. CAS No. 341031-54-7. Pack Sizes: 100mg, 250mg, 500mg. US Biological Life Sciences. | Worldwide |
| Tafetinib | Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibits stem cell factor receptor (Kit) , vascular endothelial growth factor receptor-2 (VEGFR-2) , platelet-derived growth factor receptor-β (PDGFR-β) , glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET) , and Fms-like tyrosine kinase-3 (FLT3) with IC 50 values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation of PDGFR-β and VEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SIM010603. CAS No. 1032265-57-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-116116. | |
| TAK-593 | TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. Synonyms: TAK593; TAK 593. Grades: >98%. CAS No. 1005780-62-0. Molecular formula: C23H23N7O3. Mole weight: 445.483. | |
| Tandutinib | Tandutinib, also known as MLN 518, is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Synonyms: MLN0518, MLN 518, MLN-518, MLN518, NSC726292, NSC 726292, NSC-726292, CT53518, CT-53518, CT 53518, D06005, D-06005, D 06005, Tandutinib. Grades: >98%. CAS No. 387867-13-2. Molecular formula: C31H42N6O4. Mole weight: 562.715. | |
| thymidine phosphorylase | The enzyme in some tissues also catalyses deoxyribosyltransferase reactions of the type catalysed by EC 2.4.2.6, nucleoside deoxyribosyltransferase. Group: Enzymes. Synonyms: pyrimidine phosphorylase; thymidine-orthophosphate deoxyribosyltransferase; animal growth regulators, blood platelet-derived endothelial cell growth factors; blood platelet-derived endothelial cell growth factor; deoxythymidine phosphorylase; gliostatins; pyrimidine deoxynucleoside phosphorylase; thymidine:phosphate deoxy-D-ribosyltransferase. Enzyme Commission Number: EC 2.4.2.4. CAS No. 9030-23-3. Thymidine Phosphorylase. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-2668; thymidine phosphorylase; EC 2.4.2.4; 9030-23-3; pyrimidine phosphorylase; thymidine-orthophosphate deoxyribosyltransferase; animal growth regulators, blood platelet-derived endothelial cell growth factors; blood platelet-derived endothelial cell growth factor; deoxythymidine phosphorylase; gliostatins; pyrimidine deoxynucleoside phosphorylase; thymidine:phosphate deoxy-D-ribosyltransferase. Cat No: EXWM-2668. | |
| Thymidine Phosphorylase from Escherichia coli, Recombinant | An enzyme that catalyzes the reversible conversion of thymidine to thymine. Thymidine phosphorylase is part of the pyrimidine nucleoside salvage pathway. This pathway allows pyrimidine bases to be recycled for nucleotide biosynthesis, while the pentose 1-phosphates are converted to intermediates of the pentose phosphate shunt and glycolysis. The E. coli thymidine phosphorylase shares 40% sequence homology with the human sequence, which has been found to be identical to the angiogenic agent platelet-derived endothelial growth factor. The purified E. coli enzyme has been shown to stimulate blood vessel growth in chick chorioallantoic membrane assays. Applications: ...hosphate deoxy-D-ribosyltransferase; EC 2.4.2.4; 9030-23-3. Enzyme Commission Number: EC 2.4.2.4. CAS No. 9030-23-3. Thymidine Phosphorylase. Activity: Type I, > 900 units/mL, aseptically filled; Type II, > 500 units/mL. Storage: 2-8°C. Form: buffered aqueous solution, Solution in 0.5 M potassium phosphate containing 2 mM uracil, 0.02% sodium azide and bovine serum albumin. Source: E. coli. Species: Escherichia coli. thymidine phosphorylase; pyrimidine phosphorylase; thymidine-orthophosphate deoxyribosyltransferase; animal growth regulators, blood platelet-derived endothelial cell growth factors; blood platelet-derived endothelial cell growth factor; deoxythymidi | |
| Tovetumab | Tovetumab is a human IgG2κ monoclonal antibody that binds to human platelet-derived growth factor receptor alpha (PDGFRα) and blocks receptor signal transduction by PDGF ligands. Synonyms: MEDI-575; MEDI 575; MEDI575. CAS No. 1243266-04-7. | |
| Trapidil | Trapidil, also called as Rocornal, is a platelet aggregation inhibitor with specific platelet-derived growth factor. Uses: Vasodilator agents. Synonyms: N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-aminerapidilRocornalTrapymin15421-84-8AvantrinTrapymineTrapidil; AR 12008; AR-12008; AR12008Trapidilum [INN-Latin]UNII-EYG5Y6355EMLS000567667N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amineEINECS 239-434-2. CAS No. 15421-84-8. Molecular formula: C10H15N5. Mole weight: 205.26. | |
| Trapidil | Trapidil is a vasodilator, an antiplatelet active molecule with specificity for platelet-derived growth factor. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AR-12008. CAS No. 15421-84-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-B1016. | |
| TSU-68 | TSU-68 is a inhibitor that targets vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor β, and fibroblast growth factor receptor 1. The inhibitory effects of TSU-68 towards these growth factors lead to substantial antitumor activity and showed potential in its development in therapeutic uses. Group: Biochemicals. Alternative Names: (Z)-3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic Acid; 3-[2,4-Dimethyl-5-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propionic Acid; 3-[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-methylidenyl]-2-indolinone; 5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid; NSC 702827; Orantinib; SU 6668. Grades: Highly Purified. CAS No. 252916-29-3. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| VEGFR2 Kinase Inhibitor II | VEGFR2 kinase inhibitor II is a reversible and cell-permeable inhibitor of VEGFR2's kinase activity with IC50 value of 70 nM. It also less potently inhibits the platelet-derived growth factor receptor β (PDGFRβ) with IC50 value of 920 nM, and other related receptor as well as non-receptor tyrosine kinases. Synonyms: (Z)-5-Bromo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one. Grades: ≥95%. CAS No. 288144-20-7. Molecular formula: C17H15BrN2O. Mole weight: 343.2. | |
Our database is helping our users find suppliers everyday.
